Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies

Costas Lallas, MD
Published: Tuesday, Aug 29, 2017



Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Checkpoint inhibitors are generating more interest, states Lallas. As far as the T-cell response goes, there are agents which can move the immune process ahead. There are stimulating agents, which are being looked at actively in clinical trials.

Checkpoint inhibitors allow T cells to be activated, as well as the cellular response against those malignancies, which is why they have shown efficacy, explains Lallas.
 


Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Checkpoint inhibitors are generating more interest, states Lallas. As far as the T-cell response goes, there are agents which can move the immune process ahead. There are stimulating agents, which are being looked at actively in clinical trials.

Checkpoint inhibitors allow T cells to be activated, as well as the cellular response against those malignancies, which is why they have shown efficacy, explains Lallas.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x